OncoMatch/Clinical Trials/NCT04467723
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Is NCT04467723 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Atezolizumab for nsclc stage iv.
Treatment: Atezolizumab — The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR actionable mutation
de novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1)
Excluded: ALK actionable mutation
de novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1)
Excluded: ROS1 actionable mutation
de novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR/ ALK/ ROS-1)
Allowed: PD-L1 (CD274) TPS < 1%
PDL1 TPS score less than 1% or unknown: first-line must be PD1/PDL1 inhibitor in combination with chemotherapy
Disease stage
Required: Stage IV, I, II, III
de novo stage IV or recurrent NSCLC ... at least 1 measurable lesion; Early stage (I-III) NSCLC treated with adjuvant or neoadjuvant chemotherapy then PD1/PDL1 inhibitor treatment for recurrent disease; Recurrent Unresectable stage III NSCLC treated with prior chemoradiation followed by maintenance PD1/PDL1 inhibitor with measurable disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy — metastatic
previously treated with either PD-1 / PD-L1 or the combination of PD1/PDL1 and cytotoxic chemotherapy
Must have received: anti-PD-L1 therapy — metastatic
previously treated with either PD-1 / PD-L1 or the combination of PD1/PDL1 and cytotoxic chemotherapy
Cannot have received: investigational agent
Has received investigational agents within 14 days or 5 half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment
Cannot have received: monoclonal antibody
Exception: denosumab
Prior monoclonal antibody within 4 weeks before study Day 1 Exception: The use of denosumab
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate hematologic function; Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Kansas Cancer Center (KUCC) · Fairway, Kansas
- The University of Kansas Cancer Center, Westwood Campus · Kansas City, Kansas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify